Navigation Links
TorreyPines Therapeutics Reports Third Quarter 2007 Results
Date:11/14/2007

and pharmacokinetics of tezampanel

given once-daily for four consecutive days. Data from this multiple

dose trial are intended to support the continued development of

tezampanel for the treatment of migraine, as well as allow TorreyPines

to consider expanding the development of tezampanel into additional

chronic pain conditions.

-- Completed a Phase I multiple-dose clinical trial of NGX267 in

development for cognitive impairment associated with schizophrenia

(CIAS). NGX267 was found to be safe and well-tolerated. The clinical

trial also demonstrated that NGX267 increases salivary flow, which may

be beneficial in treating xerostomia, or dry mouth.

-- Extended the genetics discovery collaboration with Eisai Co., Ltd.

This agreement focuses on the discovery of Alzheimer's disease targets

using whole-genome family-based association screening. Under terms of

the agreement, TorreyPines received an upfront payment and continued

research funding in support of the program for an additional year.

Financial Results

Revenue for the three month period ended September 30, 2007 was $2.5 million compared to revenue of $2.5 million for the same period in 2006. Operating expenses for the quarter ended September 30, 2007 were $9.5 million, with $8.2 million attributable to research and development. This compares to operating expenses of $5.2 million and research and development expenses of $4.5 million for the same period last year. The Company reported a net loss for the quarter ended September 30, 2007 of $6.8 million compared to a net loss of $2.7 million for the same period last year.

Revenue for the nine month period ended September 30, 2007 was $7.4 million compared to revenue of $7.4 million for the same period in 2006. Operating expenses for the nine month period were $24.6 million, with $20.4 million attributabl
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014 Kamal Rashid , PhD, ... and Training Center (BETC) and research professor of biology ... 2014 , an international two-day event focused on biomanufacturing ... Global Summits, the event will bring together leaders of ... to develop and produce human therapeutics. “The growth curve ...
(Date:9/23/2014)... VA (PRWEB) September 23, 2014 ATCC, ... is pleased to announce two important appointments to the ... Executive Vice President of Strategy and Technology and Dr. ... for the Standards Resource Center. Both roles are new ... H. Cypess, President and CEO at ATCC described the ...
(Date:9/23/2014)... Sept. 23, 2014  Age Defying Dermatology ® , ... has become one of the first clinics in the ... aesthetic laser for tattoo removal. The treatment safely and ... "For years, tattoo removal has been a lengthy, painful, ... "This is an opportunity to erase tattoo pigment more ...
(Date:9/23/2014)... 23, 2014   GenoSpace , a precision medicine ... tools to enable the broad use of genomic data ... has been awarded Phase I of a Fast Track ... Institutes of Health (NIH) to enable enhanced data access ... http://photos.prnewswire.com/prnh/20140922/147649 During the past ...
Breaking Biology Technology:Worcester Polytechnic Institute's Biomanufacturing Expertise to be Featured in Berlin 2Worcester Polytechnic Institute's Biomanufacturing Expertise to be Featured in Berlin 3ATCC Announces New Appointments to its Leadership Team 2ATCC Announces New Appointments to its Leadership Team 3Age Defy Now Offers World's Most Advanced Technology for Tattoo Removal 2GenoSpace Awarded Fast Track SBIR Grant to Enable Data Access and Cohort Construction for Biorepositories 2
... MILWAUKEE Catalyst International, a global provider of ... suite of platform-independent SCE applications. , ,"We're expanding ... customers' increasing demand for integrated fulfillment solutions from ... boundaries," said Jim Treleaven, President and CEO of ...
... WAUKESHA, WI. - RedPrairie Corporation , has ... electronic product code (EPC)-compliant radio frequency identification ... in a real-world environment. The RFID Lab is ... tag placement and readability as they prepare for ...
... supports plans for growth and strategic investments , ... and services company, today announced it has signed a ... Merchants and Manufacturers BanCorp (MMBC) , a Milwaukee-based ... credit, from which no monies have been drawn, was ...
Cached Biology Technology:RedPrairie Builds RFID Lab - Enables Real-World Testing 2
(Date:9/22/2014)... University researchers are studying a potential new treatment that ... in which scars develop in the lungs and severely ... miR-29, which is delivered to lung tissue intravenously. In ... reversed fibrosis after several days. , The findings ... Molecular Medicine . , "The mimic, when injected into ...
(Date:9/22/2014)... Rochelle, NY, September 22, 2014Cassava, also known as tapioca, ... yields in areas of Africa, Asia, and Latin America ... the availability of novel enzymes and processes designed to ... be used to produce sweeteners such as glucose, fructose, ... to corn, as described in a Review article in ...
(Date:9/22/2014)... Antarctic fishes that manufacture their own "antifreeze" ... also suffer an unfortunate side effect, researchers report: ... bodies resist melting even when temperatures warm. ... Proceedings of the National Academy of Sciences . ... undesirable consequence of the evolution of antifreeze proteins ...
Breaking Biology News(10 mins):Reversing the effects of pulmonary fibrosis 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 3
... HOLLYWOOD, Calif., Aug. 20, 2012 (Pinksheets: MDBX) ( www.medboxinc.com ... 2nd quarter 2012 financials, which showed earnings of over $820,000 ... has almost doubled since the beginning of the year, and ... Medbox earns all its revenue through consulting services and the ...
... Southampton and the National Oceanography Centre, Southampton has found ... increase the bleaching susceptibility of reef corals. Corals ... a layer of living tissue covering the calcareous skeletons. ... within the coral polyps. The coral animal ...
... effort at Arizona State University to educate and train ... by the National Science Foundation (NSF). Through its Integrative ... is providing $3 million to ASU to help develop ... with the skills needed to find solutions to the ...
Cached Biology News:Medbox, Inc. Releases 2nd Quarter Financials 2Improving water quality can help save coral reefs 2ASU awarded $3 million to research solar energy technologies, launch energy Ph.D. program 2
...
... Continuing a tradition of progressive centrifuge design ... series. The Centra-CL3 and Centra-CL3R (refrigerated) general ... laboratory., Quality Control Over Sample Preparation ... lock up to 99 protocols and has ...
PP2B-Abeta (C-20)...
... 8-iso PGE2 is one of several isoprostanes ... is a potent renal vasoconstrictor in the rat. ... with IC50 values of 0.5 and 5 µM, ... the rat at a concentration of 4 mg/kg/min, ...
Biology Products: